PERRIGO COMPANY PLC

PRGO trades at a 15.58% short float—notably elevated for a pharma name—while the RSI of 45.1 suggests neither oversold nor overbought territory. The missing P/E ratio signals recent unprofitability, a red flag in pharmaceutical preparations where margin consistency typically underpins valuation. At $1.6B market cap, this is a small-cap player facing headwinds significant enough to erase earnings power. The company sits well below its 52-week high despite reasonable momentum indicators, implying the market has priced in structural concerns. Short interest near 16% could represent legitimate conviction about deteriorating fundamentals rather than a squeeze setup, warranting scrutiny of recent earnings and pipeline health.